Distributor inventory | Tablet
Vildagliptin 50 mg + Metformin hydrochloride 500 mg + Dapagliflozin 10 mg (tablet)
Type 2 diabetes mellitus (T2DM) in adults, as an add-on to diet and exercise when dual therapy is inadequate; helps improve glycaemic control (fasting and post-meal glucose, HbA1c).
Vildagliptin (a DPP-4 inhibitor) increases incretin levels, enhancing glucose-dependent insulin release and reducing glucagon. Metformin reduces hepatic glucose production and improves insulin sensitivity. Dapagliflozin (an SGLT2 inhibitor) increases urinary glucose excretion by reducing renal glucose reabsorption.
Oral tablet. Take exactly as prescribed, usually once daily with food (preferably with the main meal) to reduce stomach upset from metformin; swallow whole with water. Maintain adequate hydration; follow diet/exercise plan and monitor blood glucose as advised.
Common side effects of VILDAMAC TRIO 500 TAB may include:
For prescription use only. Not for type 1 diabetes or diabetic ketoacidosis. Metformin may rarely cause lactic acidosis—risk increases with kidney impairment, dehydration, sepsis, heavy alcohol use, or hypoxia; stop and seek urgent care if severe weakness, fast breathing, abdominal pain or drowsiness occur. Dapagliflozin can cause dehydration/low BP, genital mycotic infections, UTIs and rare euglycaemic ketoacidosis—seek care for nausea/vomiting, abdominal pain, rapid breathing. Assess renal function before and during therapy; avoid/adjust in significant renal impairment. Withhold temporarily during acute illness, reduced intake, major surgery, or before iodinated contrast procedures as advised. Monitor for hypoglycaemia when used with insulin or sulfonylureas.
